In fact, PMP is currently being upgraded, to fix ANKRD26 and FLT3 coverage, to target further genes related to predisposition to MN, and to include analysis of common rearrangements in myeloid disorders (through RNA sequencing) (e.g. BCR-ABL1 for Chronic Myeloid Leukemia, PML-RARA for Acute Promyelocytic Leukemia, etc.). This evidence concerns the gene ANKRD26 and chronic myelogenous leukemia, BCR-ABL1 positive.